Syncromune™ is well-positioned to develop a scalable platform for long-term, sustained growth. Our innovative technology provides the potential to treat numerous types of metastatic solid tumor cancers.
Syncromune™ is a privately held, clinical stage biopharmaceutical company dedicated to the development of better immunotherapies for metastatic solid tumor cancers. We are at the forefront of developing combination immunotherapies, which several thought leaders consider to be the future of cancer therapy. We are committed to bringing life-changing treatments to patients with unmet medical needs by fighting cancer in a new way.
The company is currently developing Syncrovax™, a proprietary platform technology that uses a combination approach to synchronize the timing and location of tumor neoantigen release with the functional activation and education of immune cells. An in situ vaccine is created from the patient’s own tumor antigens, making it a personalized treatment for each patient. The platform is designed to educate T cells to induce a systemic anti-tumor response at the site of the treated tumor as well as metastases throughout the body.
Syncromune, Inc. Enters into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., Ltd. https://t.co/617YOehYqkRead More
RT @CancerResearch: June kicks off Cancer Immunotherapy Month™. Let's fuel the next scientific discoveries and breakthrough treatments thro…Read More
Mathematical method developed to predict cancer and drug-specific immunotherapy efficacy via @medical_xpressRead More
New clues to prostate cancer: Why aggressive subtype can resist treatment via @medical_xpressRead More
The information contained in our press releases and presentations should be considered accurate only as of the date it was originally issued. Syncromune™ disavows any obligation to update the information contained in these press releases and presentations after the date of their issuance.